...
首页> 外文期刊>International Journal of Pharmaceutics >Preparation and evaluation of biodegradable microspheres containing a new potent osteogenic compound and new synthetic polymers for sustained release.
【24h】

Preparation and evaluation of biodegradable microspheres containing a new potent osteogenic compound and new synthetic polymers for sustained release.

机译:制备和评估可生物降解的微球,其中含有新型有效的成骨化合物和新型合成聚合物,以实现持续释放。

获取原文
获取原文并翻译 | 示例

摘要

In order to achieve the sustained release of 3-ethyl-4-(4-methylisoxazol-5-yl)-5-(methylthio) thiophene-2-carboxamide (BFB0261), a new potent osteogenic compound for the treatment of bone disorders, we prepared microspheres containing BFB0261 and newly synthesized three poly (D, L-lactic acid) (PLA), four poly (D, L-lactic acid-co-glycolic acid) (PLGA), and eight poly (D, L-lactic acid)-block-poly(ethylene glycol) (PLA-PEG) biodegradable polymers or copolymers, and evaluated the release pattern of BFB0261 from the microspheres in vitro and in vivo. The mean particle size of the microspheres, except for the microspheres constructed from PLA-PEG with a greater than 20% PEG component, was in the range of approximately 10-50 microm, and the preparations showed a spherical shape with a smooth surface. In an in vitro release study, the release of BFB0261 from PLA-1 (Mw: 36 kDa), PLAPEG9604H (PLA/PEG ratio: 96:4, Mw: 181 kDa), or PLAPEG8317 (PLA/PEG ratio: 83:17, Mw: 106 kDa) microspheres occurred in a zero-order manner with a slow release, and more than 50% of BFB0261 remained in each type of microsphere at 12 weeks after incubation. When the BFB0261 microspheres constructed from various polymers were intramuscularly administered to the rat femur, the microspheres constructed from PLA-1 or PLAPEG9604H were able to achieve a sustained release of BFB0261 at the injection site for 6 weeks. The present information indicates that microspheres constructed from PLA-1 or PLAPEG9604H may be feasible for bone engineering.
机译:为了实现3-乙基-4-(4-甲基异恶唑-5-基)-5-(甲硫基)噻吩-2-羧酰胺(BFB0261)的持续释放,这是一种新型的强效成骨化合物,可用于治疗骨骼疾病,我们制备了含有BFB0261的微球,并新合成了三个聚(D,L-乳酸)(PLA),四个聚(D,L-乳酸-乙醇酸)(PLGA)和八个聚(D,L-乳酸)酸)-嵌段-聚(乙二醇)(PLA-PEG)可生物降解的聚合物或共聚物,并评估了BFB0261在体外和体内从微球的释放方式。除了由具有大于20%的PEG组分的PLA-PEG构成的微球以外,微球的平均粒径在约10-50微米的范围内,并且制剂显示出具有光滑表面的球形。在体外释放研究中,BFB0261从PLA-1(Mw:36 kDa),PLAPEG9604H(PLA / PEG比:96:4,Mw:181 kDa)或PLAPEG8317(PLA / PEG比:83:17)释放,Mw:106kDa)微球以零级方式发生并缓慢释放,并且在孵育后12周时,每种类型的微球中剩余超过50%的BFB0261。当将由多种聚合物构成的BFB0261微球肌肉注射给大鼠股骨时,由PLA-1或PLAPEG9604H构成的微球能够在注射部位持续释放BFB0261 6周。目前的信息表明,由PLA-1或PLAPEG9604H构成的微球可用于骨骼工程。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号